Australian researchers used artificial intelligence to design de novo proteins that inhibit the growth of antibiotic-resistant bacteria such as Escherichia coli by blocking hemoglobin transporters essential for bacterial survival. These AI-generated proteins demonstrate potential as novel antimicrobial agents. Concurrently, Iambic Therapeutics and Revolution Medicines launched a multi-year collaboration combining AI drug discovery platforms to accelerate oncology drug candidate development. Revolution Medicines will integrate Iambic’s NeuralPLexer and PropANE AI models for protein-ligand interaction predictions and lead optimization, with deal value up to $25 million.